Clinical Pharmacology of Dopamine Agonists in Parkinson's Disease

ISSN： 1170-229X

Source： Drugs & Aging, Vol.13, Iss.5, 1998-11, pp. : 381-389

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dopamine agonists in Parkinson’s disease

By Tintner Ron Jankovic Joseph

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 11, 2003-11 ,pp. : 1803-1820

Informa Healthcare

Access to resources Recommend Favorite

The safety of dopamine agonists in the treatment of Parkinson's disease

By Bonuccelli Ubaldo Ceravolo Roberto

Expert Opinion on Drug Safety, Vol. 7, Iss. 2, 2008-03 ,pp. : 111-127

Informa Healthcare

Access to resources Recommend Favorite

Clinical Review and Treatment of Select Adverse Effects of Dopamine Receptor Agonists in Parkinson's Disease

By Wood Lindy D.

Drugs & Aging, Vol. 27, Iss. 4, 2010-04 ,pp. : 295-310

Adis International

Access to resources Recommend Favorite

Are Dopamine Receptor Agonists Neuroprotective in Parkinson's Disease?

By Le W-D. Jankovic J.

Drugs & Aging, Vol. 18, Iss. 6, 2001-06 ,pp. : 389-396

Adis International

Access to resources Recommend Favorite

The Role of Dopamine Agonists in the Treatment of Depression in Patients with Parkinson's Disease: A Systematic Review

By Leentjens Albert F.G.

Drugs, Vol. 71, Iss. 3, 2011-02 ,pp. : 273-286

Adis International

Access to resources Recommend Favorite